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Asthma management: can we further improve
compliance and outcomes?
The prevalence of asthma is continuing to rise
throughout the world, particularly amongst chil-
dren. International asthma management guidelines
are widely disseminated and national guidelines
have been introduced in many countries around the
world. However, asthma is frequently uncontrolled,
and still may cause death, despite the availability
of effective pharmacological therapy. To date,
advancement in asthma management has been
pharmacologically driven, rather than device-dri-
ven. Problems with drug delivery have been
identified due to inappropriate use of inhaler
devices, particularly pressurised metered dose
inhalers (pMDIs) where patients need to coordinate
inhaler activation with inspiration. However, as
inhalation is likely to remain the route-of-delivery
of choice for the foreseeable future, it is vital that
new inhalation devices be sought which effectively
and consistently deposit therapeutic agent into the
lungs, are environmentally friendly, cost-effective
and improve patient compliance.
A satellite symposium held during the 12th
Annual Congress of the European Respiratory
Society in Stockholm, Sweden, from 14 to 18
September 2002, reviewed several issues surround-
ing the management of patients with asthma. In
particular, current asthma management guidelines
were reviewed in terms of their usefulness, limita-
tions and future developments.
Asthma management guidelines are used in most
countries around the world and have been impor-
tant in improving the management of asthma. The
principles of modern asthma therapy, and overall
goal of every asthma management programme, are
to achieve control of the disease. In the ‘real’
world asthma remains poorly controlled and the
reasons for this anomaly (despite the widespread
availability of effective pharmacological therapy)
are numerous. For example, the guidelines them-
selves have numerous inherent flaws such as
complexity and excessive length and are based on
scientific evidence which may be biased and not
representative of the general population of pa-
tients with asthma. Secondly, patients frequently
do not adhere to their treatment regimen for a
variety of reasons including incorrect use of inhaler
and underestimation of disease severity. Indeed,
asthma severity is often mis-classified in the first
instance, and inappropriate or insufficient therapy
prescribed. Finally, although guidelines agree on
the most appropriate therapy to control asthma,
the method by which this therapy is delivered to
the lungs is neglected. Since it is likely that in the
future inhaled b2-agonists and inhaled corticoster-
oids (ICSs) will remain the cornerstone of asthma
therapy, development of inhalation devices will
become more important than development of new
drugs.
Inappropriate use of inhaler devices contributes
to lack of asthma control. Clearly, there is a need to
develop inhaler devices which are easy to use and
deliver a consistent dose of drug to the lungs which
may improve patient compliance with treatment
leading to better control of asthma. At present, the
Global Initiative for Asthma (GINA) guidelines
recommend that inhaler devices be portable, easy
to operate (especially for children), not require
power, require minimal cooperation and coordina-
tion and have minimal maintenance requirements.
Dry powder inhalers (DPIs) or breath-actuated MDIs
are recommended for children aged 46 years.
Consideration of patient preference and ability to
correctly use the device are factors advocated by
the British Thoracic Society when deciding on which
inhaler to use.
Although inhalation therapy is likely to continue
to dominate asthma treatment, at present only
three methods of delivery are mostly used in
clinical practice: nebulisers, pMDIs and DPIs.
Pressurised MDIs have many problems associated
with them such as the need for good coordination
between inhaler activation and patient inhalation
and intensive training. They are also environmen-
tally unfriendly and deposition rates depend on
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inhaler technique. DPIs, as a class of inhalation
device, overcome several of these problems as they
are breath-activated and do not contain propel-
lants. Although DPIs do offer both the patient and
the physician several advantages over pMDIs,
individually they do have some limitations of
design, cost-effectiveness and/or user friendliness.
The ideal inhaler should have an innovative design
which combines simplicity of use with effective
performance. It should also have a low intrinsic
resistance ensuring that it is easy to use even in
patients with severe airflow obstruction. Feedback
mechanisms are important in order to check for
compliance and give both the patient and physician
confidence that a correct and exact single dose has
been inhaled. The inhaler device should be con-
venient to use, generate a high quality aerosol, and
be reliable as well as durable in a range of
temperature and humidity conditions. Finally, the
ideal inhaler should be cost-effective and envir-
onmentally friendly.
My introductory presentation (S8–S9) reviews
current asthma management guidelines and their
application to the ‘real world’, discusses problems
associated with the guidelines and outlines future
asthma therapy. O’Connor (S10–S16) reviews the
problems associated with pMDIs and reviews how
the many features of the new Multidose Dry Powder
Inhaler, the Novolizers overcome these limitations
and those of other DPIs. Kohler (S17–S21) discusses
how the device characteristics of the Novolizers
translate into benefits of drug deposition, thera-
peutic efficacy, easy of use, cost-effectiveness and
patient compliance. Finally, Cegla (S22–S28) de-
scribes a randomised cross-over study in patients
with mild asthma which was conducted to compare
patient technique and inspiratory characteristics of
the Turbuhalers and the Novolizers.
The symposium concluded that inhalation ther-
apy is likely to remain the cornerstone of asthma
management for the foreseeable future. Current
asthma management guidelines are sensible and
based on the best available scientific evidence, but
in the future they need to consider the inhaler
devices as well to. Inhaler devices should be easy to
use and give consistent and accurate dose delivery.
In the future, improvements in inhaler technology
may be more important than developing new
pharmacological therapies. An ideal inhaler should
improve drug delivery and patient compliance with
therapy and may contribute to achieving asthma
control, which is the aim of asthma management
guidelines.
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